Form 4: Alnylam CCO Sells Shares Under 10b5-1 Plan
Insider Trading Report (Form 4)
Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, sold 3,474 shares of common stock on August 29, 2025, through a pre-arranged 10b5-1 trading plan.
Summary
- Tolga Tanguler, EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), sold a total of 3,474 shares of common stock.
- The sales occurred on August 29, 2025, at weighted average prices ranging from $445.53 to $452.49 per share.
- These transactions were executed under a Rule 10b5-1(c) trading plan adopted by Mr. Tanguler on May 27, 2025.
- Following these transactions, Mr. Tanguler beneficially owns 25,992 shares of Alnylam common stock directly.
Sentiment
Score: 5
Explanation: While insider selling can be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates the immediate negative sentiment, as it indicates the sales were scheduled in advance rather than being prompted by new, adverse information.
Positives
- The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a lack of new discretionary selling intent.
Negatives
- An executive officer sold a significant number of shares (3,474 shares) of company stock.
Risks
- The primary risk related to this filing is the potential negative perception of insider selling, even if pre-planned, which could impact investor sentiment.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing.
Industry Context
This filing is a routine disclosure of insider trading activity, common across all publicly traded industries, including biotechnology. It does not provide specific industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Adoption | Tolga Tanguler adopted a Rule 10b5-1(c) trading plan, effective May 27, 2025, to pre-arrange sales of company stock. | 05/27/2025 | This plan provides an affirmative defense against insider trading allegations by scheduling transactions in advance, enhancing transparency and compliance with SEC regulations. |
Stakeholder Impact
- Shareholders: May view the insider selling with caution, although the 10b5-1 plan provides context and mitigates concerns about discretionary selling based on new information.
Key Dates
| Date | Description |
|---|---|
| 05/27/2025 | Rule 10b5-1(c) trading plan adopted by Tolga Tanguler. |
| 08/29/2025 | Date of common stock transactions (sales). |
| 09/02/2025 | Date the Form 4 was signed. |
Recommendation
holdThe filing reports routine insider selling under a pre-arranged 10b5-1 plan. While insider selling can sometimes signal a lack of confidence, the pre-planned nature of these sales reduces that implication. Without additional company-specific news or financial performance data, this Form 4 alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate as it's a neutral event in the context of a pre-planned sale.
Keywords
Alnylam Pharmaceuticals, ALNY, Insider Trading, Form 4, Tolga Tanguler, Chief Commercial Officer, Stock Sale, 10b5-1 Plan, Executive Compensation, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.